CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 80 enrolled
Drug / intervention
Ketorolac tromethamine ophthalmic solution 0.45%drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02646072
NCT02646072Phase 4Completed
CompareCT.gov

The Effect of Preoperative Topical Ketorolac 0.45% on Aqueous Cytokine Levels and Macular Thickness in Diabetic and Non Diabetic Patients Undergoing Cataract Surgery

University of Malaya·interventional·Posted Jan 5, 2016·Updated Jan 5, 2016

In Brief

A Phase 4 clinical trial evaluating Ketorolac tromethamine ophthalmic solution 0.45% for Cystoid Macular Edema, Postoperative and Diabetes Mellitus. Completed, enrolled 80 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether there is a relationship between inflammatory cytokines in the aqueous of the eye and thickness of the macula after treatment of topical ketorolac for patients undergoing cataract surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCystoid Macular Edema, Postoperative, Diabetes Mellitus
CountriesMalaysia
Collaborators--

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 5, 2016
Enrollment StartAug 1, 2014
Primary CompletionMay 1, 2015
Study CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 10.5 years ago

Interventions

Ketorolac tromethamine ophthalmic solution 0.45%drug

Indicated for the treatment of pain and inflammation following cataract surgery.